Ying Shibo, Jiang Zhaoqiang, He Xianglei, Yu Min, Chen Riping, Chen Junqiang, Ru Guoqing, Chen Yuan, Chen Wanyuan, Zhu Lijin, Li Tao, Zhang Yixiao, Guo Xinnian, Yin Xianhong, Zhang Xing, Lou Jianlin
Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China.
Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, China.
Dis Markers. 2017;2017:5756102. doi: 10.1155/2017/5756102. Epub 2017 Mar 1.
High-mobility group box 1 (HMGB1) functions as a proinflammatory cytokine and is one of the most intriguing molecules in inflammatory disorders and cancers. Notably, HMGB1 is a potential therapeutic target and novel biomarker in related diseases. However, the diagnostic value of HMGB1 for benign and malignant asbestos-related diseases (ARDs) remains unclear. In this work, we detected preoperative serum HMGB1 levels in Chinese asbestos-exposed (AE) and ARDs populations and further evaluated the diagnostic value of HMGB1 in patients with certain types of ARDs, including those with pleural plaques, asbestosis, or malignant mesothelioma (MM). The experimental data presented that the serum level of HMGB1 was significantly elevated in AE and ARDs subjects. Our findings indicated that serum HMGB1 is a sensitive and specific biomarker for discriminating asbestosis- and MM-affected individuals from healthy or AE individuals. In addition, serum matrix metalloproteinases 2 and 9 are not correlated with HMGB1 in ARDs. Thus, our study provides supporting evidence for HMGB1 as a potential biomarker either for the clinical diagnosis of high-risk AE cohorts or for evaluating ARDs.
高迁移率族蛋白B1（HMGB1）作为一种促炎细胞因子，是炎症性疾病和癌症中最引人关注的分子之一。值得注意的是，HMGB1是相关疾病潜在的治疗靶点和新型生物标志物。然而，HMGB1对良性和恶性石棉相关疾病（ARDs）的诊断价值仍不明确。在本研究中，我们检测了中国石棉暴露（AE）人群和ARDs患者术前血清HMGB1水平，并进一步评估了HMGB1在某些类型ARDs患者中的诊断价值，这些患者包括胸膜斑、石棉肺或恶性间皮瘤（MM）患者。实验数据表明，AE人群和ARDs患者血清HMGB1水平显著升高。我们的研究结果表明，血清HMGB1是区分石棉肺和MM患者与健康或AE个体的敏感且特异的生物标志物。此外，在ARDs中，血清基质金属蛋白酶2和9与HMGB1不相关。因此，我们的研究为HMGB1作为高危AE人群临床诊断或评估ARDs的潜在生物标志物提供了支持性证据。
